ARVO 2025: Rishi Singh, MD, discusses real-world clinical outcomes in patients with DME

At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network spoke with Rishi Singh, MD, vice president and CMO, Cleveland Clinic Martin North and South Hospitals. At the meeting in Salt Lake City, Utah, Dr. Singh presented a poster highlighting the real-world durability of faricimab in patients with diabetic macular edema (DME), using data from the IRIS Registry.

The study analyzed nearly 1,200 eyes and found improvements in the annualized number of injections for both previously treated and treatment-naive patients. "We found that in both the previously-treated eyes and the treatment-naive eyes, that there was a improvement in the annualized number of injections they received," Dr. Singh said. "We also saw a stability of those patients who were previously treated in regards to the visual acuity, and we saw an improvement in visual acuity in those patients who were previously treatment-naive."

Additionally, retinal thickness among patients with DME reduced by almost 60 microns from baseline, with no significant intraocular inflammation. "Always, the safety has remained very top notch and without any significant intraocular inflammation or any other serious conditions," Dr Singh said. "This, again, is validated in a real-world population."